Myriad Genetics, Inc.

How big is Myriad Genetics, Inc.?

As of Jun 18, Myriad Genetics, Inc. has a market capitalization of 459.04 million, with net sales of 831.30 million and a net profit of -101.40 million over the latest four quarters. The company reported shareholder's funds of 701.10 million and total assets of 1,027.60 million as of Dec 24.

Market Cap: As of Jun 18, Myriad Genetics, Inc. has a market capitalization of 459.04 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Myriad Genetics, Inc. reported net sales of 831.30 million and a net profit of -101.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 701.10 million and total assets of 1,027.60 million.

What does Myriad Genetics, Inc. do?

Myriad Genetics, Inc. is a molecular diagnostic company focused on developing and marketing diagnostic tests in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $196 million and has a market cap of $459.04 million.

Overview:<BR>Myriad Genetics, Inc. is a molecular diagnostic company engaged in the discovery, development, and marketing of transformative molecular diagnostic tests within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 196 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 459.04 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.03<BR>- Return on Equity: -9.36%<BR>- Price to Book: 0.65<BR><BR>Contact Details:<BR>- Address: 320 S Wakara Way, SALT LAKE CITY UT: 84108-1214<BR>- Tel: 1 801 5843600<BR>- Fax: 1 801 5843640<BR>- Website: http://www.myriad.com

Should I buy, sell or hold Myriad Genetics, Inc.?

Who are in the management team of Myriad Genetics, Inc.?

As of March 2022, the management team of Myriad Genetics, Inc. includes S. Louise Phanstiel (Independent Chairman), Paul Diaz (CEO), and several independent directors: Heiner Dreismann, Rashmi Kumar, Dennis Langer, Lee Newcomer, and Colleen Reitan. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Myriad Genetics, Inc. includes the following individuals:<BR><BR>- Ms. S. Louise Phanstiel, Independent Chairman of the Board<BR>- Mr. Paul Diaz, President, Chief Executive Officer, Director<BR>- Dr. Heiner Dreismann, Independent Director<BR>- Ms. Rashmi Kumar, Independent Director<BR>- Dr. Dennis Langer, Independent Director<BR>- Dr. Lee Newcomer, Independent Director<BR>- Ms. Colleen Reitan, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Myriad Genetics, Inc. overvalued or undervalued?

As of November 4, 2019, Myriad Genetics, Inc. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 0.67, a negative EV to EBITDA of -15.22, and a year-to-date stock return of -43.98%, significantly underperforming compared to its peers and the S&P 500.

As of 4 November 2019, the valuation grade for Myriad Genetics, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. Given the current metrics, the company appears to be overvalued, particularly with a Price to Book Value of 0.67 and an EV to Sales ratio of 0.54, which suggest that the market is not pricing in sufficient value relative to its assets and sales. Additionally, the negative EV to EBITDA of -15.22 further underscores the challenges the company faces in generating earnings.<BR><BR>In comparison to its peers, Myriad Genetics, Inc. has a significantly lower EV to EBITDA ratio than Owens & Minor, Inc. at 4.7461 and Pacific Biosciences of California, Inc. at -4.2891, indicating that it is struggling more than its competitors in terms of operational efficiency. Furthermore, the company's stock has underperformed relative to the S&P 500, with a year-to-date return of -43.98% compared to the index's 12.22%, reinforcing the notion that it is currently overvalued.

Is Myriad Genetics, Inc. technically bullish or bearish?

As of September 8, 2025, Myriad Genetics, Inc. shows a mildly bearish technical trend with mixed signals across time frames, having underperformed the S&P 500 significantly over the past year and five years.

As of 8 September 2025, the technical trend for Myriad Genetics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals across time frames. The daily moving averages are mildly bearish, while the Bollinger Bands show a bullish stance weekly but mildly bearish monthly. The KST is bullish weekly but bearish monthly, and the Dow Theory indicates no trend weekly and mildly bullish monthly. Overall, the technical stance is mildly bearish due to the predominance of bearish indicators, particularly in the moving averages and monthly metrics. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 over the past year, down 73.02% compared to the S&P's 17.14% gain, and has also lagged over longer periods, including a 5-year decline of 40.6% against the S&P's 96.61% increase.